- Discover
- /
- SNOA
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About SNOA
8/4/2025
Comprehensive Analysis
Financial Health
- Liquidity & Solvency: Sonoma Pharmaceuticals (SNOA) maintains a strong current ratio (3.34) and quick ratio (2.12), indicating robust short-term liquidity. However, total equity has declined from $11.17M in 2021 to $4.87M in 2024, reflecting weakening solvency. No long-term debt mitigates immediate solvency risk, but declining equity and persistent net losses ($3.75M TTM) signal financial strain.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing